At the Fast Company Innovation Festival last week, Redwire Chief Scientist Dr. Ken Savin spoke about Redwire’s cutting-edge Pharmaceutical In-space Laboratory (PIL-BOX) technology and Redwire’s new entity, SpaceMD. Following the event, Dr. Savin spoke to NYSE live about the exciting work Redwire is doing to advance in-space pharmaceutical research. Below, find a few key highlights from the interview:

• Redwire’s biotechnology facilities have been an integral part of NASA’s International Space Station (ISS) research strategy, providing critical scientific research in drug development, cancer research, and tissue engineering,
• Redwire has flown 32 PIL-BOX systems to the ISS. The company is consistently launching and bringing back pharmaceutical drugs and science to and from space for customers like Bristol Myers Squibb, Eli Lilly and Company, along with Butler and Purdue University
• Redwire recently formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics.

Watch the NYSE live segment here: